Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications

• Published in: Cell death & disease Vol. 14; no. 9; p. 586
• Main Authors: Fang, Jianwen, Lu, Yue, Zheng, Jingyan, Jiang, Xiaocong, Shen, Haixing, Shang, Xi, Lu, Yuexin, Fu, Peifen
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 04.09.2023; Springer Nature B.V; Nature Publishing Group
• Subjects: 631/67/327; 631/80/86; Angiogenesis; Antibodies; Biochemistry; Biomedical and Life Sciences; Cell Biology; Cell Culture; Cell proliferation; Endothelial cells; Immune checkpoint; Immune response; Immunology; Immunomodulation; Immunotherapy; Life Sciences; Metastases; Molecular modelling; Review; Review Article; Stromal cells; Therapeutic targets; Tumor microenvironment; Tumors
• ISSN: 2041-4889; 2041-4889
• DOI: 10.1038/s41419-023-06119-x

The tumor microenvironment (TME) is a highly intricate milieu, comprising a multitude of components, including immune cells and stromal cells, that exert a profound influence on tumor initiation and progression. Within the TME, angiogenesis is predominantly orchestrated by endothelial cells (ECs), which foster the proliferation and metastasis of malignant cells. The interplay between tumor and immune cells with ECs is complex and can either bolster or hinder the immune system. Thus, a comprehensive understanding of the intricate crosstalk between ECs and immune cells is essential to advance the development of immunotherapeutic interventions. Despite recent progress, the underlying molecular mechanisms that govern the interplay between ECs and immune cells remain elusive. Nevertheless, the immunomodulatory function of ECs has emerged as a pivotal determinant of the immune response. In light of this, the study of the relationship between ECs and immune checkpoints has garnered considerable attention in the field of immunotherapy. By targeting specific molecular pathways and signaling molecules associated with ECs in the TME, novel immunotherapeutic strategies may be devised to enhance the efficacy of current treatments. In this vein, we sought to elucidate the relationship between ECs, immune cells, and immune checkpoints in the TME, with the ultimate goal of identifying novel therapeutic targets and charting new avenues for immunotherapy.